#USA #New Orleans #28bio #CNS-3D #Myelinated Organoids

28bio Launches CNS-3D Myelinated Organoids for Drug Efficacy

In a groundbreaking development in the field of neurotechnology, 28bio has unveiled its CNS-3D Myelinated Organoids, a sophisticated tool aimed at transforming the assessment of therapies for neurodegenerative diseases. This innovative organoid model is explicitly designed to quantify drug-induced demyelination, observe natural remyelination, and evaluate various therapeutic strategies focused on repairing myelin. This dual capability allows researchers to capture both injury and recovery processes within a single biological framework.

Historically, the understanding of myelination and the processes involved in demyelinating diseases have heavily relied on animal models. However, these models often present a distorted representation of human conditions due to the rapid and complete myelin loss and repair observed in animals compared to the slower and often incomplete remyelination path followed in humans. The CNS-3D Myelinated Organoids aim to bridge this critical translational gap by providing a more accurate platform for studying human myelin dynamics and its implications in various neurodegenerative diseases.

The CNS-3D Myelinated Organoids are adeptly structured to include neurons, astrocytes, and oligodendrocytes, forming a complex three-dimensional architecture. This configuration not only enables the creation of myelinated axons but also facilitates the assessment of functional neural activities concurrently with determining structural and molecular endpoints. Christopher Butt, PhD, Vice President of Technology at 28bio, emphasized the significance of this advancement, stating, "We are no longer dependent on unreliable animal models to understand myelin disease biology. For the first time, therapies can be evaluated in an assay-ready human model that directly measures myelin dynamics and functional neural activity."

As the prevalence of multiple sclerosis (MS) has surged by sixfold over the past four decades, with disease-modifying therapies failing at rates exceeding 99%, the need for more effective research models has never been more critical. The limitations experienced with existing therapies highlight the growing demand for innovative approaches that can accurately model the myelination process and provide insights into the functional deficits observed in a range of neurodegenerative conditions, including Alzheimer's, Parkinson's, and Huntington's diseases.

As cell and gene therapies emerge, the challenge of restoring or preserving myelin becomes increasingly complex. Accurate targeting of oligodendrocytes and the demand for sustained functional repair are paramount. According to Stuart Gibb, Head of Business Development at 28bio, the anticipation surrounding the CNS-3D Myelinated Organoids has been overwhelmingly positive, reflecting the evident deficiencies of animal models currently in use. He noted, "The model is available as a service today, with assay-ready 96- and 384-replicate formats shipping globally in Q3'26." This launch represents a pivotal moment in advancing human-relevant assays capable of faithfully modeling disease pathogenesis and tracking functional recovery processes in neurodegenerative diseases.

Explore the potential of 28bio’s CNS-3D Myelinated Organoids by contacting them directly for more information.

About 28bio

28bio is at the forefront of neurotechnology innovation, engineering human brains at scale to exhibit memory, learning, and cognitive functions. Its proprietary Nexon™ platform synergizes tissue engineering, neural interfacing, and artificial intelligence to combat today’s neurological health challenges by improving the predictability of therapeutic outcomes in humans. The company is dedicated to upholding high ethical standards as it develops brain organoid technology and engineered human cognition, paving the way for revolutionary advancements in healthcare.